| Year |
Citation |
Score |
| 2024 |
Liu L, van Schaik TA, Chen KS, Rossignoli F, Borges P, Vrbanac V, Wakimoto H, Shah K. Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice. Frontiers in Immunology. 14: 1324618. PMID 38274817 DOI: 10.3389/fimmu.2023.1324618 |
0.339 |
|
| 2023 |
Moleirinho S, Kitamura Y, Borges PSGN, Auduong S, Kilic S, Deng D, Kanaya N, Kozono D, Zhou J, Gray JJ, Revai-Lechtich E, Zhu Y, Shah K. Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer. Stem Cells Translational Medicine. PMID 37311043 DOI: 10.1093/stcltm/szad033 |
0.344 |
|
| 2023 |
Kanaya N, Kitamura Y, Lopez Vazquez M, Franco A, Chen KS, van Schaik TA, Farzani TA, Borges P, Ichinose T, Seddiq W, Kuroda S, Boland G, Jahan N, Fisher D, Wakimoto H, ... Shah K, et al. Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas. Science Translational Medicine. 15: eade8732. PMID 37256936 DOI: 10.1126/scitranslmed.ade8732 |
0.346 |
|
| 2023 |
van Schaik TA, Moreno-Lama L, Aligholipour Farzani T, Wang M, Chen KS, Li W, Cai L, Zhang YS, Shah K. Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 162: 114665. PMID 37062216 DOI: 10.1016/j.biopha.2023.114665 |
0.401 |
|
| 2023 |
Chen KS, Reinshagen C, Van Schaik TA, Rossignoli F, Borges P, Mendonca NC, Abdi R, Simon B, Reardon DA, Wakimoto H, Shah K. Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity. Science Translational Medicine. 15: eabo4778. PMID 36599004 DOI: 10.1126/scitranslmed.abo4778 |
0.379 |
|
| 2022 |
Bhere D, Choi SH, van de Donk P, Hope D, Gortzak K, Kunnummal A, Khalsa J, Revai Lechtich E, Reinshagen C, Leon V, Nissar N, Bi WL, Feng C, Li H, Zhang YS, ... ... Shah K, et al. Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cells. Nature Communications. 13: 2810. PMID 35589724 DOI: 10.1038/s41467-022-30558-3 |
0.398 |
|
| 2022 |
Balatsoukas A, Rossignoli F, Shah K. NK cells in the brain: implications for brain tumor development and therapy. Trends in Molecular Medicine. 28: 194-209. PMID 35078713 DOI: 10.1016/j.molmed.2021.12.008 |
0.354 |
|
| 2021 |
Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H, Shah K, Alomary MN, Zaidan N. Oncolytic Herpes Simplex Virus-Based Therapies for Cancer. Cells. 10. PMID 34207386 DOI: 10.3390/cells10061541 |
0.309 |
|
| 2021 |
Vaughan HJ, Zamboni CG, Radant NP, Bhardwaj P, Revai Lechtich E, Hassan LF, Shah K, Green JJ. Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Molecular Therapy Oncolytics. 21: 377-388. PMID 34189258 DOI: 10.1016/j.omto.2021.04.004 |
0.315 |
|
| 2021 |
van Schaik TA, Chen KS, Shah K. Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy? Frontiers in Oncology. 11: 678562. PMID 34141622 DOI: 10.3389/fonc.2021.678562 |
0.355 |
|
| 2021 |
Karakaş N, Stuckey D, Revai-Lechtich E, Shah K. IL13Rα2‑ and EGFR‑targeted pseudomonas exotoxin potentiates the TRAIL‑mediated death of GBM cells. International Journal of Molecular Medicine. 48. PMID 34080646 DOI: 10.3892/ijmm.2021.4978 |
0.359 |
|
| 2021 |
Kitamura Y, Kanaya N, Moleirinho S, Du W, Reinshagen C, Attia N, Bronisz A, Revai Lechtich E, Sasaki H, Mora JL, Brastianos PK, Falcone JL, Hofer AM, Franco A, Shah K. Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. Science Advances. 7. PMID 33658202 DOI: 10.1126/sciadv.abe8671 |
0.337 |
|
| 2020 |
Jiang L, Wang YJ, Zhao J, Uehara M, Hou Q, Kasinath V, Ichimura T, Banouni N, Dai L, Li X, Greiner DL, Shultz LD, Zhang X, Sun ZJ, Curtin I, ... ... Shah K, et al. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Cell. 183: 1219-1233.e18. PMID 33242418 DOI: 10.1016/j.cell.2020.10.045 |
0.346 |
|
| 2020 |
Akter F, Simon B, de Boer NL, Redjal N, Wakimoto H, Shah K. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochimica Et Biophysica Acta. Reviews On Cancer. 1875: 188458. PMID 33148506 DOI: 10.1016/j.bbcan.2020.188458 |
0.308 |
|
| 2020 |
Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, De Biasio M, Heinelt M, Reeve B, Abdi R, Alturki M, Fallatah M, Almalik A, Alhasan AH, Shah K, et al. Shattering barriers toward clinically meaningful MSC therapies. Science Advances. 6: eaba6884. PMID 32832666 DOI: 10.1126/Sciadv.Aba6884 |
0.36 |
|
| 2020 |
Yang EY, Shah K. Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Frontiers in Oncology. 10: 1182. PMID 32793488 DOI: 10.3389/Fonc.2020.01182 |
0.349 |
|
| 2020 |
Khalsa JK, Cheng N, Keegan J, Chaudry A, Driver J, Bi WL, Lederer J, Shah K. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nature Communications. 11: 3912. PMID 32764562 DOI: 10.1038/S41467-020-17704-5 |
0.428 |
|
| 2020 |
Deng D, Shah K. TRAIL of Hope Meeting Resistance in Cancer. Trends in Cancer. PMID 32718904 DOI: 10.1016/J.Trecan.2020.06.006 |
0.355 |
|
| 2020 |
Song N, Scholtemeijer M, Shah K. Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. Trends in Pharmacological Sciences. PMID 32709406 DOI: 10.1016/J.Tips.2020.06.009 |
0.394 |
|
| 2020 |
Mineo M, Lyons SM, Zdioruk M, von Spreckelsen N, Ferrer-Luna R, Ito H, Alayo QA, Kharel P, Giantini Larsen A, Fan WY, Auduong S, Grauwet K, Passaro C, Khalsa JK, Shah K, et al. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Molecular Cell. PMID 32504554 DOI: 10.1016/J.Molcel.2020.05.015 |
0.331 |
|
| 2020 |
Lee YH, Pang SW, Revai Lechtich E, Shah K, Simon SE, Ponnusamy S, Narayanan R, Poh CL, Tan KO. Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1. Journal of Cancer Research and Clinical Oncology. PMID 32377840 DOI: 10.1007/S00432-020-03231-9 |
0.334 |
|
| 2020 |
Bhere D, Arghiani N, Lechtich ER, Yao Y, Alsaab S, Bei F, Matin MM, Shah K. Simultaneous downregulation of miR-21 and upregulation of miR-7 has anti-tumor efficacy. Scientific Reports. 10: 1779. PMID 32019988 DOI: 10.1038/S41598-020-58072-W |
0.301 |
|
| 2020 |
Mineo M, Lyons SM, Ferrer-Luna R, Ito H, Spreckelsen Nv, Alayo QA, Khalsa JK, Shah K, Ligon KL, Beroukhim R, Ivanov P, Anderson PJ, Nakashima H, Lawler SE, Chiocca EA. Abstract B46: The long noncoding RNA INCA1 is a novel regulator of PD-L1 expression in tumors Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-B46 |
0.338 |
|
| 2019 |
Kavari SL, Shah K. Concise Review: Targeting multiple cell surface receptors in tumors with engineered stem cells. Stem Cells (Dayton, Ohio). PMID 31381835 DOI: 10.1002/Stem.3069 |
0.461 |
|
| 2019 |
Martinez-Quintanilla J, Seah I, Chua M, Shah K. Oncolytic viruses: overcoming translational challenges. The Journal of Clinical Investigation. 130. PMID 30829653 DOI: 10.1172/Jci122287 |
0.421 |
|
| 2019 |
Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Scientific Reports. 9: 139. PMID 30644426 DOI: 10.1038/S41598-018-37437-2 |
0.368 |
|
| 2019 |
Bhere D, Hugh Choi S, van de Donk P, Khalsa J, Hope D, Gortzak K, Kunnummal A, Reinshagen C, Ling H, Vasdev N, Ibn Essayed W, Golby A, Bi W, Lowe A, Wakimoto H, ... ... Shah K, et al. EXTH-49. THERAPEUTIC EFFICACY OF ENGINEERED, HYDROGEL ENCAPSULATED BIMODAL MSC IN GLIOBLASTOMA STRATIFIED ON CELL SURFACE RECEPTOR EXPRESSION Neuro-Oncology. 21: vi93-vi93. DOI: 10.1093/Neuonc/Noz175.1188 |
0.492 |
|
| 2018 |
Kuruppu D, Bhere D, Farrar CT, Shah K, Brownell AL, Tanabe KK. A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging. Cancer Gene Therapy. PMID 30420717 DOI: 10.1038/S41417-018-0060-Z |
0.405 |
|
| 2018 |
Passaro C, Alayo Q, DeLaura I, McNulty JJ, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins WF, McLaughlin E, Fernandez S, Reardon DA, et al. Arming an oncolytic herpes simplex virus Type 1 with a single chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30279232 DOI: 10.1158/1078-0432.Ccr-18-2311 |
0.333 |
|
| 2018 |
Reinshagen C, Bhere D, Choi SH, Hutten S, Nesterenko I, Wakimoto H, Le Roux E, Rizvi A, Du W, Minicucci C, Shah K. CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors. Science Translational Medicine. 10. PMID 29997250 DOI: 10.1126/Scitranslmed.Aao3240 |
0.482 |
|
| 2018 |
Heidari P, Kunawudhi A, Martinez-Quintanilla J, Szretter A, Shah K, Mahmood U. Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. Theranostics. 8: 3380-3391. PMID 29930736 DOI: 10.7150/Thno.24017 |
0.431 |
|
| 2018 |
Bhere D, Khajuria RK, Hendriks WT, Bandyopadhyay A, Bagci-Onder T, Shah K. Therapeutic Neural Stem Cells Engineered During Different Stages of Reprogramming Reveal Varying Therapeutic Efficacies. Stem Cells (Dayton, Ohio). PMID 29451340 DOI: 10.1002/Stem.2805 |
0.499 |
|
| 2018 |
Kitamura Y, Moleirinho S, Du W, Reinshagen C, Attia N, Shah K. Stem-02. Developing Brain Metastatic Tumor Models For Targeted Stem Cell Therapy Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.1009 |
0.441 |
|
| 2017 |
Bhere D, Tamura K, Wakimoto H, Choi SH, Purow B, Debatisse J, Shah K. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro-Oncology. PMID 29016934 DOI: 10.1093/Neuonc/Nox138 |
0.365 |
|
| 2017 |
Choi SH, Stuckey DW, Pignatta S, Reinshagen C, Khalsa JK, Roozendaal NC, Martinez-Quintanilla J, Tamura K, Keles E, Shah K. Tumor resection boosts therapeutic efficacy of encapsulated stem cells expressing a highly secretable variant of interferon-β in glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28912136 DOI: 10.1158/1078-0432.Ccr-17-0077 |
0.435 |
|
| 2017 |
Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proceedings of the National Academy of Sciences of the United States of America. PMID 28710334 DOI: 10.1073/Pnas.1700363114 |
0.409 |
|
| 2017 |
Ignatius MS, Hayes MN, Lobbardi R, Chen EY, McCarthy KM, Sreenivas P, Motala Z, Durbin AD, Molodtsov A, Reeder S, Jin A, Sindiri S, Beleyea BC, Bhere D, Alexander MS, ... Shah K, et al. The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Reports. 19: 2304-2318. PMID 28614716 DOI: 10.1016/J.Celrep.2017.05.061 |
0.343 |
|
| 2017 |
Zhu Y, Bassoff N, Reinshagen C, Bhere D, Nowicki MO, Lawler SE, Roux J, Shah K. Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Scientific Reports. 7: 2602. PMID 28572590 DOI: 10.1038/S41598-017-02483-9 |
0.456 |
|
| 2017 |
Jahan N, Lee JM, Shah K, Wakimoto H. Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. International Journal of Cancer. PMID 28567859 DOI: 10.1002/Ijc.30811 |
0.474 |
|
| 2017 |
Shah K, Du W, Fisher D. Scdt-26. Stem Cell Loaded Oncolytic Viruses Track And Kill Metastatic Brain Tumors Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.1109 |
0.417 |
|
| 2017 |
Bhere D, Tamura K, Purow B, Debatisse J, Shah K. LB06 - Mesenchymal stem cells shuttle micrornas via extracellular vesicles and prime resistant GBM to caspase mediated apoptosis Cytotherapy. 19. DOI: 10.1016/J.Jcyt.2017.03.017 |
0.363 |
|
| 2016 |
Choi SH, Shah K. Engineered bifunctional proteins and stem cells: next generation of targeted cancer therapeutics. Discovery Medicine. 22: 157-166. PMID 27755970 |
0.372 |
|
| 2016 |
Shah K. Stem cell-based therapies for tumors in the brain: are we there yet? Neuro-Oncology. 18: 1066-78. PMID 27282399 DOI: 10.1093/Neuonc/Now096 |
0.499 |
|
| 2015 |
Zhu Y, Choi SH, Shah K. Multifunctional receptor-targeting antibodies for cancer therapy. The Lancet. Oncology. 16: e543-54. PMID 26545843 DOI: 10.1016/S1470-2045(15)00039-X |
0.359 |
|
| 2015 |
Bhere D, Shah K. Stem Cell-Based Therapies for Cancer. Advances in Cancer Research. 127: 159-89. PMID 26093900 DOI: 10.1016/Bs.Acr.2015.04.012 |
0.405 |
|
| 2015 |
Bagci-Onder T, Du W, Figueiredo JL, Martinez-Quintanilla J, Shah K. Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain : a Journal of Neurology. 138: 1710-21. PMID 25910782 DOI: 10.1093/Brain/Awv094 |
0.454 |
|
| 2015 |
Choi SH, Tamura K, Khajuria RK, Bhere D, Nesterenko I, Lawler J, Shah K. Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 235-43. PMID 25358253 DOI: 10.1038/Mt.2014.214 |
0.495 |
|
| 2015 |
Martinez-Quintanilla J, He D, Wakimoto H, Alemany R, Shah K. Encapsulated Stem Cells Loaded With Hyaluronidase-expressing Oncolytic Virus for Brain Tumor Therapy Molecular Therapy. 23: 108-118. PMID 25352242 DOI: 10.1038/Mt.2014.204 |
0.454 |
|
| 2015 |
Stuckey DW, Hingtgen SD, Karakas N, Rich BE, Shah K. Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells (Dayton, Ohio). 33: 589-600. PMID 25346520 DOI: 10.1002/Stem.1874 |
0.476 |
|
| 2015 |
Redjal N, Zhu Y, Shah K. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells (Dayton, Ohio). 33: 101-10. PMID 25186100 DOI: 10.1002/Stem.1834 |
0.504 |
|
| 2014 |
Stuckey DW, Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype Nature Reviews Cancer. 14: 683-691. PMID 25176333 DOI: 10.1038/Nrc3798 |
0.424 |
|
| 2014 |
Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discovery. 4: 1299-309. PMID 25139148 DOI: 10.1158/2159-8290.Cd-14-0471 |
0.319 |
|
| 2014 |
Srivastava J, Robertson CL, Rajasekaran D, Gredler R, Siddiq A, Emdad L, Mukhopadhyay ND, Ghosh S, Hylemon PB, Gil G, Shah K, Bhere D, Subler MA, Windle JJ, Fisher PB, et al. AEG-1 regulates retinoid X receptor and inhibits retinoid signaling. Cancer Research. 74: 4364-77. PMID 25125681 DOI: 10.1158/0008-5472.Can-14-0421 |
0.362 |
|
| 2014 |
Kuruppu D, Brownell AL, Shah K, Mahmood U, Tanabe KK. Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability. Cancer Research. 74: 4111-21. PMID 24876106 DOI: 10.1158/0008-5472.Can-13-3472 |
0.382 |
|
| 2014 |
Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H, Shah K. Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus Variants for Brain Tumor Therapy Journal of the National Cancer Institute. 107: 368-368. PMID 24838834 DOI: 10.1093/Jnci/Dju090 |
0.494 |
|
| 2014 |
Du W, Uslar L, Sevala S, Shah K. Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors. Plos One. 9. PMID 24748276 DOI: 10.1371/Journal.Pone.0095490 |
0.45 |
|
| 2014 |
Zhu Y, Shah K. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biology & Therapy. 15: 815-22. PMID 24658109 DOI: 10.4161/Cbt.28585 |
0.313 |
|
| 2014 |
Sullivan JP, Nahed BV, Chi AS, Madden MN, Oliveira SM, Springer S, Wakimoto H, Bhere D, Shah K, Spuhler P, Shah AM, Louis DN, Toner M, Maheswaran S, Haber DA. Abstract 4004: Molecular characterization of circulating glioblastoma cells identifies a mesenchymal-like tumor cell subpopulation Cancer Research. 74: 4004-4004. DOI: 10.1158/1538-7445.Am2014-4004 |
0.464 |
|
| 2013 |
Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends in Molecular Medicine. 19: 685-694. PMID 24076237 DOI: 10.1016/J.Molmed.2013.08.007 |
0.418 |
|
| 2013 |
Shah K. Encapsulated stem cells for cancer therapy Biomatter. 3. PMID 23507920 DOI: 10.4161/biom.24278 |
0.36 |
|
| 2013 |
Guo Y, Yuan H, Cho H, Kuruppu D, Jokivarsi K, Agarwal A, Shah K, Josephson L. High Efficiency Diffusion Molecular Retention Tumor Targeting Plos One. 8. PMID 23505478 DOI: 10.1371/Journal.Pone.0058290 |
0.381 |
|
| 2013 |
Martinez-Quintanilla J, Bhere D, Heidari P, He D, Mahmood U, Shah K. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells (Dayton, Ohio). 31: 1706-14. PMID 23389839 DOI: 10.1002/Stem.1355 |
0.532 |
|
| 2013 |
Hingtgen S, Figueiredo JL, Farrar C, Duebgen M, Martinez-Quintanilla J, Bhere D, Shah K. Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. Journal of Neuro-Oncology. 111: 153-61. PMID 23242736 DOI: 10.1007/S11060-012-1008-Z |
0.392 |
|
| 2013 |
Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 68-77. PMID 22929661 DOI: 10.1038/Mt.2012.175 |
0.464 |
|
| 2013 |
Bagci-Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K. Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene. 32: 2818-27. PMID 22824792 DOI: 10.1038/Onc.2012.304 |
0.48 |
|
| 2012 |
Nesterenko I, Wanningen S, Bagci-Onder T, Anderegg M, Shah K. Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas. Plos One. 7: e49219. PMID 23145127 DOI: 10.1371/journal.pone.0049219 |
0.339 |
|
| 2012 |
van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen en Henegouwen PM, Shah K. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. Proceedings of the National Academy of Sciences of the United States of America. 109: 16642-7. PMID 23012408 DOI: 10.1073/Pnas.1202832109 |
0.475 |
|
| 2012 |
Hingtgen S, Kasmieh R, Elbayly E, Nesterenko I, Figueiredo JL, Dash R, Sarkar D, Hall D, Kozakov D, Vajda S, Fisher PB, Shah K. A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy. Plos One. 7: e40234. PMID 22808125 DOI: 10.1371/Journal.Pone.0040234 |
0.372 |
|
| 2012 |
Srivastava J, Siddiq A, Emdad L, Santhekadur PK, Chen D, Gredler R, Shen XN, Robertson CL, Dumur CI, Hylemon PB, Mukhopadhyay ND, Bhere D, Shah K, Ahmad R, Giashuddin S, et al. Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model. Hepatology (Baltimore, Md.). 56: 1782-91. PMID 22689379 DOI: 10.1002/Hep.25868 |
0.302 |
|
| 2012 |
Kauer TM, Figueiredo JL, Hingtgen S, Shah K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas Nature Neuroscience. 15: 197-204. PMID 22197831 DOI: 10.1038/Nn.3019 |
0.455 |
|
| 2012 |
Shah K. Mesenchymal stem cells engineered for cancer therapy Advanced Drug Delivery Reviews. 64: 739-748. PMID 21740940 DOI: 10.1016/J.Addr.2011.06.010 |
0.455 |
|
| 2012 |
Brognaro E, Ghods A, Feinstein D, Glick R, Connolly KJ, Meetze K, Boudrow A, Gyuris J, Han M, Hingtgen S, Figueiredo J, Farrar C, Farrar C, Deubgen M, Martinez-Quintanilla J, ... ... Shah K, et al. LAB-TUMOR MODELS (IN VIVO/IN VITRO) Neuro-Oncology. 14: vi160-vi164. DOI: 10.1093/Neuonc/Nos241 |
0.388 |
|
| 2011 |
Carney BJ, Shah K. Migration and fate of therapeutic stem cells in different brain disease models Neuroscience. 197: 37-47. PMID 21946010 DOI: 10.1016/J.Neuroscience.2011.08.063 |
0.373 |
|
| 2011 |
Shah K. In vivo imaging of the dynamics of different variants of EGFR in glioblastomas Methods in Molecular Biology (Clifton, N.J.). 680: 153-164. PMID 21153380 DOI: 10.1007/978-1-60761-901-7_11 |
0.456 |
|
| 2011 |
Shah K. Imaging fate of stem cells at a cellular resolution in the brains of mice Methods in Molecular Biology (Clifton, N.J.). 680: 91-101. PMID 21153375 DOI: 10.1007/978-1-60761-901-7_6 |
0.442 |
|
| 2011 |
Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Research. 71: 154-163. PMID 21084267 DOI: 10.1158/0008-5472.Can-10-1601 |
0.444 |
|
| 2010 |
Yoo BK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, Fisher PB, Sarkar D. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Research. 70: 3249-58. PMID 20388796 DOI: 10.1158/0008-5472.Can-09-4009 |
0.313 |
|
| 2010 |
van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, Weissleder R, Shah K. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene. 29: 3185-95. PMID 20305695 DOI: 10.1038/Onc.2010.75 |
0.508 |
|
| 2010 |
Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1130-42. PMID 20179672 DOI: 10.1038/Mt.2010.29 |
0.362 |
|
| 2010 |
Hingtgen SD, Kasmieh R, van de Water J, Weissleder R, Shah K. A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. Stem Cells (Dayton, Ohio). 28: 832-41. PMID 20127797 DOI: 10.1002/Stem.313 |
0.471 |
|
| 2010 |
Emdad L, Sarkar D, Lee SG, Su ZZ, Yoo BK, Dash R, Yacoub A, Fuller CE, Shah K, Dent P, Bruce JN, Fisher PB. Astrocyte elevated gene-1: a novel target for human glioma therapy. Molecular Cancer Therapeutics. 9: 79-88. PMID 20053777 DOI: 10.1158/1535-7163.Mct-09-0752 |
0.461 |
|
| 2010 |
Bagci-Onder T, Wakimoto H, Anderegg M, Shah K. Abstract 3495: Targeting gliomas with a dual kinase inhibitor and stem-cell delivered TRAIL Cancer Research. 70: 3495-3495. DOI: 10.1158/1538-7445.Am10-3495 |
0.52 |
|
| 2009 |
Piccirillo SGM, Binda E, Fiocco R, Vescovi AL, Shah K. Brain cancer stem cells Journal of Molecular Medicine. 87: 1087-1095. PMID 19784875 DOI: 10.1007/S00109-009-0535-3 |
0.466 |
|
| 2009 |
Yoo BK, Gredler R, Vozhilla N, Su ZZ, Chen D, Forcier T, Shah K, Saxena U, Hansen U, Fisher PB, Sarkar D. Identification of genes conferring resistance to 5-fluorouracil. Proceedings of the National Academy of Sciences of the United States of America. 106: 12938-43. PMID 19622726 DOI: 10.1073/Pnas.0901451106 |
0.323 |
|
| 2009 |
Kumar AT, Chung E, Raymond SB, van de Water JA, Shah K, Fukumura D, Jain RK, Bacskai BJ, Boas DA. Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast. Optics Letters. 34: 2066-8. PMID 19572001 DOI: 10.1364/Ol.34.002066 |
0.306 |
|
| 2009 |
Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Research. 69: 3472-81. PMID 19351838 DOI: 10.1158/0008-5472.Can-08-3886 |
0.476 |
|
| 2009 |
Shah K. Imaging neural stem cell fate in mouse model of glioma Current Protocols in Stem Cell Biology. PMID 19306259 DOI: 10.1002/9780470151808.Sc05A01S8 |
0.441 |
|
| 2009 |
Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America. 106: 4822-7. PMID 19264968 DOI: 10.1073/Pnas.0806647106 |
0.516 |
|
| 2008 |
Brick AJ, McDermott DF, Clement JM, Kwabi C, Shah K, Weiner JR, Duh MS, Neary MP, Oh WK, Choueiri TK. Treatment discontinuations, dose reductions, and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14636. PMID 27950228 DOI: 10.1200/Jco.2008.26.15_Suppl.14636 |
0.301 |
|
| 2008 |
Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Molecular Cancer Therapeutics. 7: 3575-85. PMID 19001440 DOI: 10.1158/1535-7163.Mct-08-0640 |
0.51 |
|
| 2008 |
Dent P, Yacoub A, Park M, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB. Searching for a cure: gene therapy for glioblastoma. Cancer Biology & Therapy. 7: 1335-40. PMID 18708757 DOI: 10.4161/Cbt.7.9.6408 |
0.395 |
|
| 2008 |
Yip S, Shah K. Stem-cell based therapies for brain tumors. Current Opinion in Molecular Therapeutics. 10: 334-42. PMID 18683097 |
0.364 |
|
| 2008 |
Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model Journal of Neuroscience. 28: 4406-4413. PMID 18434519 DOI: 10.1523/Jneurosci.0296-08.2008 |
0.45 |
|
| 2008 |
Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus WC, Ramakrishnan V, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB, Dent P. MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biology & Therapy. 7: 917-33. PMID 18376144 DOI: 10.4161/Cbt.7.6.5928 |
0.422 |
|
| 2008 |
Corsten MF, Shah K. Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncology. 9: 376-384. PMID 18374291 DOI: 10.1016/S1470-2045(08)70099-8 |
0.417 |
|
| 2007 |
Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Research. 67: 8994-9000. PMID 17908999 DOI: 10.1158/0008-5472.Can-07-1045 |
0.417 |
|
| 2007 |
Arwert E, Hingtgen S, Figueiredo JL, Bergquist H, Mahmood U, Weissleder R, Shah K. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo Cancer Research. 67: 7335-7342. PMID 17671203 DOI: 10.1158/0008-5472.Can-07-0077 |
0.428 |
|
| 2007 |
Kock N, Kasmieh R, Weissledery R, Shah K. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL1 Neoplasia. 9: 435-442. PMID 17534449 DOI: 10.1593/Neo.07223 |
0.431 |
|
| 2006 |
Shah K, Breakefield XO. HSV amplicon vectors for cancer therapy. Current Gene Therapy. 6: 361-70. PMID 16787187 DOI: 10.2174/156652306777592063 |
0.468 |
|
| 2005 |
Shah K, Tung CH, Breakefield XO, Weissleder R. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 926-31. PMID 15922963 DOI: 10.1016/J.Ymthe.2005.01.017 |
0.445 |
|
| 2005 |
Shah K. Current advances in molecular imaging of gene and cell therapy for cancer Cancer Biology and Therapy. 4: 518-523. PMID 15908803 DOI: 10.4161/Cbt.4.5.1706 |
0.361 |
|
| 2005 |
Shah K, Weissleder R. Molecular optical imaging: applications leading to the development of present day therapeutics. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 2: 215-25. PMID 15897946 DOI: 10.1602/Neurorx.2.2.215 |
0.345 |
|
| 2005 |
Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, Breakefield XO. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology. 57: 34-41. PMID 15622535 DOI: 10.1002/Ana.20306 |
0.485 |
|
| 2004 |
Shah K, Hsich G, Breakefield XO. Neural precursor cells and their role in neuro-oncology. Developmental Neuroscience. 26: 118-30. PMID 15711055 DOI: 10.1159/000082132 |
0.456 |
|
| 2004 |
Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Therapy. 11: 1175-87. PMID 15141158 DOI: 10.1038/Sj.Gt.3302278 |
0.352 |
|
| 2004 |
Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, Weissleder R, Breakefield XO, Tung CH. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia (New York, N.Y.). 6: 95-105. PMID 15140398 DOI: 10.1593/Neo.03214 |
0.319 |
|
| 2004 |
Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Research. 64: 3236-42. PMID 15126365 DOI: 10.1158/0008-5472.Can-03-3516 |
0.444 |
|
| 2004 |
Kim DE, Schellingerhout D, Ishii K, Shah K, Weissleder R. Imaging of stem cell recruitment to ischemic infarcts in a murine model. Stroke. 35: 952-7. PMID 14988578 DOI: 10.1161/01.Str.0000120308.21946.5D |
0.351 |
|
| 2004 |
Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO, Weissleder R. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Research. 64: 273-8. PMID 14729634 DOI: 10.1158/0008-5472.Can-03-1123 |
0.323 |
|
| 2004 |
Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X, Weissleder R. In vivo tracking of neural progenitor cell migration to glioblastomas. Human Gene Therapy. 14: 1247-54. PMID 12952596 DOI: 10.1089/104303403767740786 |
0.435 |
|
| 2003 |
Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene. 22: 6865-72. PMID 14534533 DOI: 10.1038/Sj.Onc.1206748 |
0.434 |
|
| 2001 |
Shah K, Schmidt ED, Vlak JM, de Vries SC. Expression of the Daucus carota somatic embryogenesis receptor kinase (DcSERK) protein in insect cells. Biochimie. 83: 415-21. PMID 11368849 DOI: 10.1016/S0300-9084(01)01257-3 |
0.301 |
|
| Show low-probability matches. |